ATE253588T1 - Nukleinsäure-abgabesystem - Google Patents

Nukleinsäure-abgabesystem

Info

Publication number
ATE253588T1
ATE253588T1 AT95927594T AT95927594T ATE253588T1 AT E253588 T1 ATE253588 T1 AT E253588T1 AT 95927594 T AT95927594 T AT 95927594T AT 95927594 T AT95927594 T AT 95927594T AT E253588 T1 ATE253588 T1 AT E253588T1
Authority
AT
Austria
Prior art keywords
pct
carbon atoms
nucleic acid
acyl group
group derived
Prior art date
Application number
AT95927594T
Other languages
English (en)
Inventor
Robert Whittaker
Fiona Helen Cameron
Veronika Bender
Minoo Moghadham
Philip Anthony Jennings
Original Assignee
Commw Scient Ind Res Org
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commw Scient Ind Res Org filed Critical Commw Scient Ind Res Org
Application granted granted Critical
Publication of ATE253588T1 publication Critical patent/ATE253588T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95927594T 1994-08-16 1995-08-16 Nukleinsäure-abgabesystem ATE253588T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPM7476A AUPM747694A0 (en) 1994-08-16 1994-08-16 Delivery of nucleic acids and peptides
AUPM7677A AUPM767794A0 (en) 1994-08-16 1994-08-25 Delivery of nucleic acids and peptides
PCT/AU1995/000505 WO1996005218A1 (en) 1994-08-16 1995-08-16 Delivery of nucleic acids

Publications (1)

Publication Number Publication Date
ATE253588T1 true ATE253588T1 (de) 2003-11-15

Family

ID=25644738

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95927594T ATE253588T1 (de) 1994-08-16 1995-08-16 Nukleinsäure-abgabesystem

Country Status (14)

Country Link
US (1) US5906922A (de)
EP (1) EP0777679B1 (de)
JP (1) JP3763577B2 (de)
CN (1) CN1210290C (de)
AT (1) ATE253588T1 (de)
AU (3) AUPM747694A0 (de)
CA (1) CA2197653C (de)
DE (1) DE69532081T2 (de)
DK (1) DK0777679T3 (de)
FI (1) FI970648A7 (de)
NO (1) NO970651L (de)
NZ (1) NZ290757A (de)
RU (1) RU2160278C2 (de)
WO (1) WO1996005218A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) * 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
EP0874910A4 (de) * 1995-06-07 1999-04-21 Life Technologies Inc Durch peptide erhöhte kationische lipid transfektionen
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
EP0775751A3 (de) * 1995-11-22 1998-06-10 F. Hoffmann-La Roche Ag Zelltransfektion
AUPN741696A0 (en) * 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
NZ512244A (en) 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
AU2001260467A1 (en) * 2000-05-30 2001-12-11 Ich Productions Limited Integrin-targeting vectors having enhanced transfection activity
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
CA2469623C (en) * 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
AUPS145602A0 (en) * 2002-03-28 2002-05-09 Commonwealth Scientific And Industrial Research Organisation Composition and method for killing tumours
EP1545432A4 (de) * 2002-09-26 2007-03-14 Pfizer Prod Inc Verwendung von hilfsstoffen zur erhöhung der dna-aufnahme durch schweine-muskelzellen
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
EP1938843A1 (de) * 2006-12-19 2008-07-02 Novosom AG Lipide und Lipidanordnungen mit transfektionsverstärkenden Elementen
EP1935434A1 (de) * 2006-12-19 2008-06-25 Novosom AG Konstruktion und Verwendung von transfektionsverstärkenden Elementen
WO2008074487A2 (en) * 2006-12-19 2008-06-26 Novosom Ag Lipids and lipid assemblies comprising transfection enhancer elements
EP2681326A4 (de) * 2011-02-28 2016-11-09 Politechnic Inst Univ New York Herstellung von peptidgemischen durch proteasekatalyse zur herstellung nützlicher biologischer und physikalischer eigenschaften
US9895005B2 (en) * 2014-05-21 2018-02-20 Kids Ii, Inc. Convertible child seat
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
US12428641B2 (en) 2017-09-15 2025-09-30 Commonwealth Scientific And Industrial Research Organisation RNA molecules
EP4559896A4 (de) * 2022-07-19 2025-10-22 Univ Hokkaido Nat Univ Corp Ph-sensitive kationische lipid- und lipidnanopartikel
CN116496193B (zh) * 2023-03-10 2026-01-02 圣诺生物医药技术(苏州)有限公司 一种氨基酸脂质形成的纳米递送系统及其应用
WO2025140190A1 (en) * 2023-12-25 2025-07-03 Microbio (Shanghai) Co., Ltd. Carbon chain-modified nucleic acids and uses thereof for bacterial cell delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
DK0506748T3 (da) * 1989-12-22 1996-01-22 Commw Scient Ind Res Org Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer
SE465221B (sv) * 1989-12-29 1991-08-12 Berol Nobel Ab Saett att kovalent binda proteiner till hydrofila ytor
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JP2958076B2 (ja) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
DE69230855D1 (de) * 1991-07-26 2000-05-04 Commw Scient Ind Res Org System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung
DE69233046T2 (de) * 1991-10-24 2004-03-04 Isis Pharmaceuticals, Inc., Carlsfeld Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2131620A1 (en) * 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
US5329029A (en) * 1992-11-05 1994-07-12 Wan Barbara Y Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
CA2160878A1 (en) * 1993-04-19 1994-10-27 Medisorb Technologies International L.P. Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression
CA2167818A1 (en) * 1993-08-02 1995-02-09 Robert George Whittaker Therapeutic compound - fatty acid conjugates

Also Published As

Publication number Publication date
JPH10509862A (ja) 1998-09-29
AUPM747694A0 (en) 1994-09-08
NO970651D0 (no) 1997-02-12
DE69532081D1 (de) 2003-12-11
DE69532081T2 (de) 2004-09-09
WO1996005218A1 (en) 1996-02-22
US5906922A (en) 1999-05-25
CA2197653C (en) 2009-04-28
DK0777679T3 (da) 2003-12-01
EP0777679A4 (de) 1997-10-08
CA2197653A1 (en) 1996-02-22
RU2160278C2 (ru) 2000-12-10
FI970648L (fi) 1997-04-07
NZ290757A (en) 2000-09-29
FI970648A0 (fi) 1997-02-14
NO970651L (no) 1997-04-02
AU3158595A (en) 1996-03-07
CN1210290C (zh) 2005-07-13
EP0777679A1 (de) 1997-06-11
CN1158619A (zh) 1997-09-03
AU684383B2 (en) 1997-12-11
FI970648A7 (fi) 1997-04-07
JP3763577B2 (ja) 2006-04-05
EP0777679B1 (de) 2003-11-05
AUPM767794A0 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
ATE253588T1 (de) Nukleinsäure-abgabesystem
ATE215078T1 (de) Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
DE59603910D1 (de) Hitzeschild mit befestigung für auspuffanlagen
ES2073706T3 (es) Nuevos derivados de acidos fosfono-alcanopolicarboxilicos y sus utilizaciones.
GB9412590D0 (en) Organic compounds
SE8403931L (sv) Treo-3-amino-2-hydroxi-4-oxosmorsyraderivat
DE3062609D1 (en) Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds
ES2118564T3 (es) Agente de limpieza para superficies duras.
ATE165337T1 (de) Verfahren zur herstellung von festen esterquats
NZ502837A (en) Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the DNA polymerase of hepatitis B virus (HBV)
KR840005733A (ko) 무라밀 펩타이드의 제조방법
ATE204252T1 (de) Verfahren zur herstellung von fettsäurepolyethylenglycolestern
ATE223915T1 (de) Neue heterozyklische chemie
MX9605737A (es) Transfeccion de celulas.
DE69507139D1 (de) Verfahren zur herstellung von 4-amino-delta 4-3-ketosteroiden via 4-nitro-delta-4-3-ketosteroiden
DE69633281D1 (de) Etherderivate von pseudopterosin
DE59408751D1 (de) Verfahren zur Herstellung von Fettsäureamiden und ihre Verwendung
DE69809205D1 (de) Verfahren zur herstellung von azyklischen nukleosiden
GEP19970937B (en) Method of producing derivatives of muramyldipeptide
EP0331756A4 (en) Agents for prophylaxis and treatment of thrombopenia
MX9604924A (es) 2,3-dihidroxipropil-2-(1-oxoalquil)amino-2-desoxiglucopiranosidos, un procedimiento para su preparacion y su uso.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties